CeriBell (NASDAQ:CBLL) Sees Large Volume Increase - Here's What Happened

Key Points

• CeriBell shares rose 12.4% to $20.765 as trading volume more than doubled to approximately 690,708 shares, reflecting heightened investor interest after its earnings release and FDA announcement.
• The company reported second-quarter revenue of $28.1 million, ahead of expectations, and received FDA clearance for two AI enhancements to its Neurology Portal. However, its quarterly loss of $0.51 per share was wider than analysts expected.
• Analyst sentiment remains generally positive, with BTIG and Canaccord maintaining “buy” ratings and price targets of $28 and $26, respectively. CeriBell also faces risks from continued losses and recent insider selling.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) saw strong trading volume on Tuesday . Approximately 690,708 shares changed hands during trading, an increase of 109% from the previous session's volume of 330,413 shares.The stock last traded at $20.7650 and had previously closed at $19.30.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and set a $28 price target, implying roughly 33% potential upside from the referenced share price. The endorsement suggests the firm expects further appreciation based on CeriBell’s growth prospects. Benzinga
• Positive Sentiment: CeriBell received FDA 510(k) clearance for two AI enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction. The tools are designed to help neurologists identify abnormal EEG patterns, reduce signal interference and interpret critical-care recordings more efficiently. The clearance could improve the clinical value of CeriBell’s platform and support hospital adoption. FDA clearance announcement
• Positive Sentiment: Second-quarter revenue was $28.1 million, exceeding the $27.28 million analyst consensus. Management also issued fiscal 2026 revenue guidance of $114 million to $117 million, with the low end matching consensus expectations. CeriBell second-quarter results
• Neutral Sentiment: Trading volume was substantially above the stock’s recent average, indicating heightened investor interest following the FDA announcement and earnings release.
• Negative Sentiment: CeriBell reported a second-quarter loss of $0.51 per share, wider than the $0.45–$0.47 consensus loss and worse than the $0.38 loss recorded a year earlier. The company continues to report negative profitability metrics, including a negative net margin and return on equity. CeriBell Q2 earnings report
• Negative Sentiment: Recent reported insider activity showed sales without purchases, which may create an overhang for sentiment, though such transactions do not necessarily indicate a change in the company’s outlook.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of analyst reports. Weiss Ratings lowered CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, July 14th. BTIG Research reissued a "buy" rating and issued a $28.00 target price on shares of CeriBell in a research note on Tuesday. Finally, Canaccord Genuity Group upped their target price on shares of CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $22.00.

CeriBell Trading Up 12.4%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The firm has a market capitalization of $822.79 million, a price-to-earnings ratio of -13.31 and a beta of 0.81. The business has a fifty day moving average price of $18.55 and a 200 day moving average price of $19.08.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. As a group, equities analysts forecast that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Insider Activity

In related news, Director Joseph Michael Taylor sold 5,500 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the sale, the director directly owned 61,573 shares in the company, valued at approximately $1,133,558.93. This represents a 8.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 202,368 shares of the business's stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the transaction, the insider owned 3,765,054 shares in the company, valued at approximately $75,752,886.48. This represents a 5.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 300,685 shares of company stock worth $5,935,326. Insiders own 17.70% of the company's stock.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently bought and sold shares of CBLL. BlackRock Inc. purchased a new stake in shares of CeriBell during the second quarter valued at approximately $37,657,000. Bank of New York Mellon Corp grew its holdings in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company's stock valued at $26,797,000 after purchasing an additional 1,162,200 shares in the last quarter. KCM Capital Inc purchased a new stake in CeriBell during the 4th quarter worth $21,930,000. TimesSquare Capital Management LLC purchased a new stake in CeriBell during the 2nd quarter worth $15,182,000. Finally, Royce & Associates LP acquired a new position in CeriBell in the 4th quarter worth $11,695,000.

CeriBell Company Profile

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source